期刊文献+

恶性肿瘤p53基因异常、nm23表达与化疗敏感性关系 被引量:3

ASSOCIATION BETWEEN p53 GENE ABNORMALITY、nm23 EXPRESSION AND CHEMOSENSITIVITY IN MALIGNANT TUMORS
下载PDF
导出
摘要 目的探讨恶性肿瘤p53基因异常、nm23表达与抗癌药耐药性关系。方法用MTT法测定17种常用抗癌药对74例恶性肿瘤的体外敏感性,并用聚合酶反应———单链构象多态分析技术和免疫组织化学染色法检测其p53基因异常、nm23表达情况。结果与p53基因正常、nm23(+)组比较,其余三组抗癌药抑制率较小,其中p53基因正常、nm23(-)组抗癌药抑制率不存在显著差异;p53基因异常、nm23(+)组对两种抗癌药抑制率存在显著差异;p53基因异常、nm23(-)组对7种抗癌药抑制率存在显著差异。结论当恶性肿瘤中存在p53基因异常或nm23表达(-)时,抗癌药耐药性增加。 PURPOSE In order to find out the relationship between p53 gene abnormality、nm23 expression and antitumor drug′s resistance in malignant tumors,and to explore the mechanism of antitumor drug resistance.METHODS To test the in vitro chemosensitivity of 74 malignant tumors for 17 antitumor drugs using MTT asay,and to detect p53 gene abnormality、nm23 expression using polymerase chain reaction(PCR) single strand conformation polymorphism and immunohistochemical method.RESULTS Compared with p53 gene normal、nm23(+) group,the inhibition rates of the antitumor drugs were lower in the other three groups.No significant difference was found between the p53 gene normal、nm23(+) group and p53 gene normal、nm23(-) group. There existed significant differences between p53 gene normal、nm23(+) group and p53 gene abnormal、nm23(+) group in 2 antitumor drugs,it was also present between p53 gene normal、nm23(+) group and p53 gene abnormal、nm23(-) group in 7 antitumor drugs.CONCLUSION When p53 gene abnormality or nm23(-) was present in malignant tumor,the antiumor drug resistance increased.The influence of p53 gene abnormality on the antitumor drug resistance was higer than low expression nm23.When p53 gene abnormality and nm23(-) coexisted in malignant tumors,the antitumor drug resistance was further increased.
出处 《中国癌症杂志》 CAS CSCD 1999年第1期26-28,共3页 China Oncology
关键词 P53基因 NM23 肿瘤 基因表达 药物疗法 药敏性 MTT Chemosensitivity Polymerase chain reaction p53 gene nm23 Apoptosis
  • 相关文献

参考文献3

二级参考文献13

  • 1辛华雯,王润帮,杜光祖,林鲁杰.十种常用抗癌药体外敏感性与临床疗效相关性研究[J].中国医院药学杂志,1994,14(12):548-550. 被引量:29
  • 2郭卫,王申五,冯传汉,任侠飞.骨肉瘤标本中p53抗癌基因异常的研究[J].中华外科杂志,1994,32(7):412-415. 被引量:6
  • 3杨建民,国外医学遗传学分册,1992年,10卷,5页
  • 4张学,国外医学遗传学分册,1992年,5卷,225页
  • 5J.K wilson,J.M.Sargent,A.W.Elgie,et al,A feasibility.study of the MTT assay for chemosensitivity testing in ovarian malignancy. British Journal of Cancer . 1990
  • 6Toshibaru Furakawa MD,Testuto Kubota MD,Akihiko Suto MD et al.Clinical usefulness.of chemosensitivity testing using the MTT assay. Journal of Surgery . 1992
  • 7R.Pieters,D.R.Huismans,A.Leyva,et al.Comparison of the rapid automated MTT-assay with a dye exclusion assay for chemosensityvity testing in child hood leukaomia. British Journal of Cancer . 1989
  • 8Yoshiro Saikawa.Tesuro Kubota,Toshihara Furukawa,et al.Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Japanese Journal of Cancer Research . 1994
  • 9H.Yamaue,H,Tanimura,K.Noguchi,et al.Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. British Journal of Cancer . 1992
  • 10Teruaki Hongo,MD.YujiFuji and Yoshio lgarashi.MD.An in vitro chemosensitivity test for the screening of an-ti-cancer drugs in childhood leukemia. Cancer . 1990

共引文献59

同被引文献23

  • 1[5]Yamaue H, Tanimura H, Noguchi K, et al. Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay[J]. Br J Cancer, 1992, 66(5): 794.
  • 2[6]Saikawa Y, Kubota T, Furukawa T, et al. Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer[J]. Jpn J Cancer Res, 1994, 85(7): 762.
  • 3[7]Ohie S, Udagawa Y, Kozu A, et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide[J]. Anticancer Res, 2000, 20(3B): 2049.
  • 4[8]Ohta I, Gorai I, Miyamoto Y, et al. Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells[J]. Cancer Lett, 2001, 162(1): 39.
  • 5[1]Lam V, McPherson JP, Salmena L, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res, 1999,23: 871-880.
  • 6[4]Nakata B, Chung KH, Ogawa M, et al. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today, 1998, 28:595-598.
  • 7[7]Lebedeva I, Rando R, Ojwang J, et al. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res, 2000, 60: 6052-6060.
  • 8[8]Luo D, Cheng SC, Xie H, et al. Effects of Bcl-2 and Bcl-xL protein levels on chemoresistance of hepatoblastoma HepG2 cell line.Biochem Cell Biol, 2000, 78: 119-126.
  • 9[11]Amundson SA, Myers TG, Scudiero D, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res, 2000, 60: 6101-6110.
  • 10[12]Lincet H, Poulain L, Remy JS, et al. The p21 (cipl/wafl) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett, 2000,161: 17-26.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部